Tested antivascular drug plus chemo versus chemo alone for TNBC
Part of Cancer, Skin clinical trials.
This Phase 3 trial compares an “anti-blood-vessel” drug added to chemotherapy versus chemotherapy alone for people with stage II–IIIC triple-negative breast cancer that has been completely removed with surgery. The goal is to see if adding the study drug improves outcomes after surgery (adjuvant treatment).
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are a woman age 18–70
- Your performance status is 0 or 1 (you can do daily activities with little or no help)
- Your breast cancer is triple-negative (no HER2, ER, or progesterone receptor) and is classified as a BLIS subtype by the study center
- Your cancer is stage IIA to IIIC and has not spread (pT1-3, N1-3, M0), and you already had surgery
- Your incision is fully healed before starting study treatment
- Your blood tests and organ function are “adequate” based on lab results done within 28 days before the first dose
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 2 study tests a chemotherapy called albumin-bound paclitaxel combined with medicines that block new blood vessel growth (antiangiogenic agents) for women with recurrent or metastatic triple-negative breast cancer. It aims to see whether this combination can better control cancer when it comes back or has spread.
This trial tests whether adding an immunotherapy drug (camrelizumab) to standard chemotherapy before surgery can improve outcomes for women with early-stage triple-negative breast cancer. The treatment is given before surgery to shrink tumors and may help prevent the cancer from coming back.
This trial tests whether using blood tests and imaging during chemotherapy and immunotherapy can help guide treatment for early-stage triple-negative breast cancer. It aims to improve outcomes by adjusting treatment based on how the cancer responds.
This trial tests a new drug called BCD-236 combined with chemotherapy for people with triple-negative breast cancer that has come back or spread. It may be an option if your cancer is AXL-positive and you have tried at least one prior treatment.
This trial tests whether adding an immunotherapy drug (HLX10) to chemotherapy before surgery, and then continuing it after surgery, helps people with triple-negative breast cancer more than chemotherapy alone. It is a type of breast cancer that does not respond to hormone treatments or HER2-targeted treatments.
This study tests whether adding an immune therapy (a PD-1 antibody) plus a blood-vessel–blocking treatment to standard chemo improves outcomes for people with surgically treated triple-negative breast cancer. Everyone gets chemotherapy, but some will also get the added drugs to try to reduce cancer coming back.
Hear when a new Breast cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.